US-Chi­na ten­sions threat­en to en­snare ad­di­tion­al Chi­nese bio­phar­ma con­trac­tors

In re­cent weeks, pro­posed fed­er­al leg­is­la­tion has forced US drug­mak­ers to re­think their re­la­tion­ship with a Chi­nese com­pa­ny that’s a sta­ple in drug de­vel­op­ment. Now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER